Stockscreener 앱 받기
3.87
0.78%
0.03
시장 영업 전:
3.90
0.03
+0.78%
전일 마감가:
$3.84
열려 있는:
$3.86
하루 거래량:
3.62M
Relative Volume:
0.65
시가총액:
$1.41B
수익:
$2.59M
순이익/손실:
$-137.89M
주가수익비율:
-4.7778
EPS:
-0.81
순현금흐름:
$-69.76M
1주 성능:
+2.93%
1개월 성능:
-33.73%
6개월 성능:
+55.42%
1년 성능:
+128.99%
1일 변동 폭
$3.84
$3.985
1주일 범위
$3.69
$3.985
52주 변동 폭
$1.15
$6.75
Atai Beckley N V Stock (ATAI) Company Profile
명칭
Atai Beckley N V
전화
49 89 2153 9035
주소
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Atai Beckley N V
|
3.87 | 1.39B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atai Beckley N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-07-29 | 개시 | Oppenheimer | Outperform |
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Beckley N V 주식(ATAI)의 최신 뉴스
ATAIAtai Beckley N.V Stock Price and Quote - Finviz
ATAI Life Sciences Files Prospectus for Share Resale - MSN
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates - ADVFN
Form 8-KCurrent report - ADVFN
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
[Form 4] Atai Beckley N.V. Insider Trading Activity - Stock Titan
H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion - MSN
Atai Beckley N.V. (ATAI) stock price, news, quote and history - Yahoo Finance Singapore
AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i - Proactive financial news
Atai Beckley NV (NASDAQ:ATAI)Shares, Dividends & News - intelligentinvestor.com.au
Enhanced (ATAI) overhauls leadership, appoints new CEO, executive chairman and CFO - Stock Titan
Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato - MSN
Atai Beckley N.V (ATAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock - Investing.com India
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
AtaiBeckley (NASDAQ: ATAI) London fireside chat at 11:30 GMT; replay for 90 days - Stock Titan
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3 - Proactive financial news
Atai Beckley Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell - MarketScreener
[8-K] ATAI Life Sciences N.V. Reports Material Event | ATAI SEC FilingForm 8-K - Stock Titan
Atai Beckley N.V. Announces Breakthrough Therapy Designation for BPL-003 and Positive Phase 2 Results for Treatment-Resistant Depression - Quiver Quantitative
Earnings Flash (ATAI) Atai Beckley N.V. Reports Q3 Revenue $749,000 - MarketScreener
Earnings Flash (ATAI) Atai Beckley Posts Q3 Net Loss $0.28 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
AtaiBeckley (NASDAQ: ATAI) closes approx. $150M offering, funding into 2029 - Stock Titan
AtaiBeckley’s BPL-003 could redefine psychedelics dosing, analysts believe - Proactive Investors
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant DepressionSlideshow (NASDAQ:ATAI) 2025-11-10 - Seeking Alpha
Atai Beckley Reports Positive Phase 2b Extension Data for Depression Treatment - MarketScreener
Why Atai Life Sciences N.V. (9VC) stock stays undervalued2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Why Atai Life Sciences N.V. (9VC) stock appears on watchlistsPortfolio Performance Report & Low Drawdown Investment Strategies - newser.com
AtaiBeckley Announces Positive Topline Data from the Phase - GlobeNewswire
Why Atai Life Sciences N.V. (9VC) stock is trending on social media2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Will Atai Life Sciences N.V. (9VC) stock justify high valuationWeekly Gains Report & Fast Exit Strategy with Risk Control - newser.com
Is Atai Life Sciences N.V. stock poised for growth2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Is Atai Life Sciences N.V. (9VC) stock nearing a technical breakoutJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
Will Atai Life Sciences N.V. stock reach all time highs in 2025Trade Ideas & Safe Capital Preservation Plans - newser.com
ATAI BECKLEY NV Insider Trades - Nasdaq
Published on: 2025-11-08 08:57:18 - newser.com
Is Atai Life Sciences N.V. (9VC) stock trading at attractive multiplesPortfolio Value Report & Stock Portfolio Risk Control - newser.com
[Form 3] ATAI Life Sciences N.V. Initial Statement of Beneficial Ownership - Stock Titan
Will Atai Life Sciences N.V. stock sustain high P E ratios2025 Market WrapUp & Fast Momentum Stock Entry Tips - newser.com
Atai Beckley N.V.: Target Price Consensus and Analysts Recommendations | ATAI | NL0015000DX5 - MarketScreener
Atai Beckley N.V.: Revenue and Earnings Analysts Forecasts Revisions | ATAI | NL0015000DX5 - MarketScreener
[Form 4] ATAI Life Sciences N.V. Insider Trading Activity - Stock Titan
9VC.SG,0P0001MXOV,0 (9VC.SG) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Combining machine learning predictions for Atai Life Sciences N.V.2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Building trade automation scripts for Atai Life Sciences N.V.July 2025 Summary & Daily Price Action Insights - newser.com
Can Atai Life Sciences N.V. stock resist sector downturnsWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Why Atai Life Sciences N.V. stock appeals to dividend seekers2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Atai Beckley N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
1.02%
자본화:
|
볼륨(24시간):